Primary refractory multiple myeloma: a real-world experience with 85 cases. Issue 12 (14th October 2020)

• Record Type: Journal Article
• Authors: Jurczyszyn, Artur; Waszczuk-Gajda, Anna; Castillo, Jorge J.; Krawczyk, Katarzyna; Stork, Martin; Pour, Ludek; Usnarska-Zubkiewicz, Lidia; Potoczek, Stanisław; Hus, Iwona; Davila Valls, Julio; Hari, Parameswaran; Chhabra, Saurabh; Gentile, Massimo; Mikala, Gabor; Varga, Gergely; Chim, Chor Sang; Fiala, Mark; Vij, Ravi; Schutz, Natalia; Rodzaj, Marek; Porowska, Agnieszka; Vesole, David H.; Druzd-Sitek, Agnieszka; Walewski, Jan; Nooka, Ajay K.
• Is Part Of: Leukemia & lymphoma. Volume 61:Issue 12(2020)
• Page Start: 2868
• Page End: 2875
• Publication Date: 2020-10-14
• Subjects: Double-refractory multiple myeloma -- prognosis -- treatment response -- survival; Leukemia -- Periodicals; Lymphomas -- Periodicals; 616.99419
• DOI: 10.1080/10428194.2020.1788014
• Languages: English
• ISSNs: 1042-8194

Abstract

Abstract: This study determined whether 85 patients with multiple myeloma (MM) double-refractory to primary induction therapy with triplet regimens had a homogenous prognosis. The overall response rate (ORR) after the second-line therapy was 51%. Patients who proceeded to immediate autologous stem cell transplantation (ASCT) had better ORR than those who received conventional therapies (62% vs. 31%). The ORR for patients who had ASCT directly after the frontline therapy was higher than for those treated with other regimens as the second line therapy (91% vs. 45%) and offered ASCT as the third-line therapy (91% vs. 55%). The median progression-free survival (PFS) after the second-line therapy and median overall survival were 21.6 months and 35.6 months, respectively. ASCT after the second line treatment (HR = 0.24) was an independent predictor of PFS. Eligible patients with primary refractory MM achieve the most benefit from ASCT, also performed immediately after first line induction therapy.